Angiotensin II type 1 and endothelin type A receptor antagonists modulate the extracellular matrix regulatory system differently in diastolic heart failure

Journal of Hypertension

Volumn 21, Issue 2, 2003, Pages 437-444

  Yoshida, Junichi ^a   Yamamoto, Kazuhiro ^a   Mano, Toshiaki ^a   Sakata, Yasushi ^a   Nishikawa, Nagahiro ^a   Miwa, Takeshi ^b   Hori, Masatsugu ^a   Masuyama, Tohru ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Angiotensin; Diastole; Endothelins; Extracellular matrix; Heart failure; Hypertension

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CANDESARTAN HEXETIL; COLLAGEN TYPE 1; COLLAGENASE 3; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; GELATINASE A; GELATINASE B; MESSENGER RNA; N [6 [2 (5 BROMO 2 PYRIMIDINYLOXY)ETHOXY] 5 (4 METHYLPHENYL) 4 PYRIMIDINYL] 4 (2 HYDROXY 1,1 DIMETHYLETHYL)BENZENESULFONAMIDE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIET; DISEASE COURSE; EXTRACELLULAR MATRIX; HEART FAILURE; HEART MUSCLE FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

EID: 0037332147     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200302000-00037     Document Type: Article

References (21)

1. Senni M, Tribouilloy CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community: a study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation 1998; 98:2282-2289.
2. Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. J Am Coll Cardiol 1999; 33:1948-1955.
3. Mosterd A, Hoes AW, de Bruyne MC, Deckers JW, Linker DT, Hofman A, et al. Prevalence of heart failure and left ventricular dysfunction in the general population: the Rotterdam Study. Eur Heart J 1999; 20:447-455.
4. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994; 13:S107-S112.
5. Dauterman KW, Massie BM, Gheorghiade M. Heart failure associated with preserved systolic function: a common and costly clinical entity. Am Heart J 1998; 135:S310-S319.
6. Doi R, Masuyama T, Yamamoto K, Doi Y, Mano T, Sakata Y, et al. Development of different phenotypes of hypertensive heart failure: systolic versus diastolic failure in Dahl salt-sensitive rats. J Hypertens 2000; 18:111-120.
7. Masuyama T, Yamamoto K, Sakata Y, Doi R, Nishikawa H, Kondo H, et al. Evolving changes in Doppler mitral flow velocity pattern in rats with hypertensive hypertrophy. J Am Coll Cardiol 2000; 36:2333-2338.
8. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Yoshida J, et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc Res 2002; 55:76-82.
9. Guarda E, Katwa LC, Myers PR, Tyagi SC, Weber KT. Effects of endothelins on collagen turnover in cardiac fibroblasts. Cardiovasc Res 1993; 27:2130-2134.
10. Dixon IMC, Ju H, Reid NL, Fleur TS, Werner JP, Jasmin G. Cardiac collagen remodeling in the cardiomyopathic syrian hamster and the effect of losartan. J Mol Cell Cardiol 1997; 29:1837-1850.
11. Masutomo K, Makino N, Sugano M, Fushiki S. Effects of losartan on the collagen degradative enzymes in hypertrophic and congestive types of cardiomyopathic hamsters. Mol Cell Biochem 2001; 224:19-27.
12. Podesser BK, Siwik DA, Eberli FR, Sam F, Ngoy S, Lambert J, et al. ETA-receptor blockade prevents matrix metalloproteinase activation late post-myocardial infarction in the rat. Am J Physiol 2001; 280:H984-H991.
13. Ammarguellat FZ, Gannon PO, Amiri F, Schiffrin EL. Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension 2002; 39:679-684.
14. Sakata Y, Masuyama T, Yamamoto K, Doi R, Mano T, Kuzuya T, et al. Renin angiotensin system-dependent hypertrophy as a contributor to heart failure in hypertensive rats: different characteristics from renin angiotensin system-independent hypertrophy. J Am Coll Cardiol 2001; 37:293-299.
15. Yamamoto K, Masuyama T, Sakata Y, Nishikawa N, Mano T, Hori M. Prevention of diastolic heart failure by endothelin type A receptor antagonist through inhibition of ventricular structural remodeling in hypertensive heart. J Hypertens 2002; 20:753-761.
16. Yamamoto K, Masuyama T, Sakata Y, Doi R, Ono K, Mano T, et al. Local neurohumoral regulation in the transition to isolated diastolic heart failure in hypertensive heart disease: absence of AT1 receptor downregulation and 'overdrive' of the endothelin system. Cardiovasc Res 2000; 46:421-432.
17. Weber KT. Targeting pathological remodeling: concepts of cardioprotection and reparation. Circulation 2000; 102:1342-1345.
18. Ito H, Hirata Y, Adachi S, Tanaka M, Tsujino M, Koike A, et al. Endothelin-1 is an autocrine/paracrine factor in the mechanism of angiotensin II-induced hypertrophy in cultured rat cardiomyocytes. J Clin Invest 1993; 92:398-403.
19. Harada M, Itoh H, Nakagawa O, Ogawa Y, Miyamoto Y, Kuwahara K, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997; 96:3737-3744.
20. Narayanan AS, Page RC. Serum regulation of collagen biosynthesis in human diploid fibroblasts. Biochem Biophys Res Commun 1987; 145:639-645.
21. Karsenty G, Park RW. Regulation of type I collagen gene expression. Intern Rev Immunol 1995; 12:177-185.